Tag: Press Release

Oncotarget | Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

November 29, 2022

“MDSCs are heterogeneous immature myeloid cells that possess important actions in immune tolerance and tumor expansion.” Listen to an audio version of this press release BUFFALO, NY- November 29, 2022… read more

Oncotarget

Oncotarget | Treasures From Trash in Cancer Research

November 23, 2022

“Most of these supposed useless data are often treated as trash and remain unexplored. However, in some cases, treasures hidden in these data are discarded [2, 4].” Listen to an… read more

Oncotarget

Oncotarget | Association of Fall Rate and Functional Status by APOE Genotype in Cancer Survivors After Exercise Intervention

November 21, 2022

“This is the first examination of the relationship among exercise, apoE genotype, and side effects and symptoms of cancer in a subset of older female cancer survivors participating in a… read more

Oncotarget

Oncotarget | Mutation Analysis Performed on Tumor Biopsies From Patients With Newly-Diagnosed Germinal Center Aggressive B Cell Lymphomas

November 17, 2022

“Our analysis demonstrates that the presence of CREBBP mutations in tumor biopsies from patients with newly-diagnosed GCB DLBCL/HGBL is associated with poorer DFS [disease free survival] following treatment with front-line… read more

Oncotarget

Oncotarget | MK256 a Novel CDK8 Inhibitor With Potent Antitumor Activity in AML Through Downregulation of STAT Pathway

November 10, 2022

“In summary, our study shows that MK256, a potent and selective CDK8 inhibitor, is an effective negative STAT pathway regulator both in vitro and in vivo in AML.” Listen to… read more

Oncotarget

Oncotarget | Tumor Hyaluronan as Novel Biomarker in Non-Small Cell Lung Cancer: A Retrospective Study

November 9, 2022

“To the best of our knowledge, there have only been 2 other studies (both retrospective) investigating the prognostic potential of HA in NSCLC patients [5, 6].” BUFFALO, NY- November 9,… read more

Oncotarget

Oncotarget | Predictive Molecular Biomarkers for Determining Neoadjuvant Chemosensitivity in Muscle Invasive Bladder Cancer

November 8, 2022

“To our knowledge, our study is the first to use combined differential mRNA and miRNA expression in MIBC to identify a NAC response signature.” BUFFALO, NY- November 8, 2022 –… read more

Oncotarget

Oncotarget | Serine Protease Matriptase Inhibits Migration and Proliferation in Multiple Myeloma Cells

November 7, 2022

“We demonstrate that matriptase overexpression in vitro was associated with reduced myeloma cell proliferation and that matriptase significantly inhibited myeloma cell migration.” BUFFALO, NY- November 7, 2022 – A new… read more

Oncotarget

Oncotarget | Nectin-4 Widely Expressed in Head and Neck Squamous Cell Carcinoma

November 3, 2022

“In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.” Listen to an audio… read more

Oncotarget

Oncotarget is Again on MEDLINE

October 27, 2022

BUFFALO, NY- October 27, 2022 – On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed. Listen to an… read more